Ropinirole transdermal - Hisamitsu

Drug Profile

Ropinirole transdermal - Hisamitsu

Alternative Names: HP 3000

Latest Information Update: 30 May 2016

Price : $50

At a glance

  • Originator Hisamitsu Pharmaceutical
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Parkinson's disease
  • Phase II Restless legs syndrome

Most Recent Events

  • 30 Jan 2015 Hisamitsu plans a phase III trial for Parkinson's Disease and Restless legs syndrome in Japan
  • 01 Dec 2014 Phase-III clinical trials in Parkinson's disease (In adults, In the elderly) in Japan (Transdermal) (JapicCTI142748)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top